Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis receives EU recommendation for cystic fibrosis treatment

Novartis receives EU recommendation for cystic fibrosis treatment

29th September 2010

Novartis has been granted a recommendation for European regulatory approval of Tobi Podhaler, a new treatment option for sufferers of cystic fibrosis (CF).

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the inhaled dry powder-based treatment as a suppressive agent against chronic Pseudomonas aeruginosa infections among CF sufferers.

Novartis has designed Tobi Podhaler to deliver the same safety and efficacy profile as its tobramycin solution drug Tobi, while reducing the time taken to administer treatment.

It is thought that the complexity of existing anti-Pseudomonas aeruginosa treatments is leading to a lack of adherence to therapy regimes.

In addition, the disposable nature of the Tobi Podhaler inhaler device helps to eliminate the risk of infection.

David Epstein, division head of Novartis Pharmaceuticals, said: "Tobi Podhaler shows how we are applying innovative technologies to better meet the needs of patients and their families."

It comes after the CHMP also recommended Novartis' new chronic myeloid leukaemia drug Tasigna for European approval earlier this month.ADNFCR-8000103-ID-800088442-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.